{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/69267a85caf6efa7038d960b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"182. ESMO Awards - Episode 2","description":"<p>ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.</p><p><br></p><p><strong>Studies:</strong></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=risk_of_recurrence__ror__after_neoadjuvant_ribocic\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>SOLTI-RIBOLARIS</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=n5_year_follow_up_results_from_the_positive__pregn\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>POSITIVE</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=monarche__primary_overall_survival__os__results_of\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>monarchE:</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=destiny_breast11__neoadjuvant_trastuzumab_deruxtec\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>DESTINY-Breast11</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=giredestrant__gire___an_oral_selective_oestrogen_r\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>evERA</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=primary_results_from_ascent_03__a_randomized_phase\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>ASCENT-03</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=first_line__1l__datopotamab_deruxtecan__dato_dxd___757d4a2\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>TROPION-Breast02 trial</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=rosella__gog3073__engotov72__apgot_ov10___relacori\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>ROSELLA</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=dice_trial__an_international_multi_centre_randomis\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>DICE trial</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=pembrolizumab_vs_placebo_plus_weekly_paclitaxel___\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>ENGOT-ov65/KEYNOTE-B96 study</strong></a></p><p><a href=\"https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=rosella__gog3073__engotov72__apgot_ov10___relacori\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>ROSELLA</strong></a></p><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!\" rel=\"noopener noreferrer\" target=\"_blank\">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\">inquisitiveonc@gmail.com</a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><p><br></p><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><p><br></p><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p>","author_name":"Michael Fernando and Josh Hurwitz"}